By Stephen Nakrosis
Shares of AnaptysBio were trading higher in the after-hours market following results from the company's rosnilimab trial as a treatment for patients with rheumatoid arthritis.
After the bell, the company's shares were trading 6.2% higher, at $25. The stock closed Tuesday's regular session with a 7.5% gain at $23.52.
The company said in a global 424-patient Phase 2b trial, its investigational rosnilimab demonstrated a best-in-disease profile in patients with moderate to severe rheumatoid arthritis. The company also said rosnilimab demonstrated favorable safety and tolerability, particularly when compared to standard of care biologics or Janus kinase inhibitors.
AnaptysBio said its ongoing Phase 2 study for rosnilimab in ulcerative colitis is on track to report initial data in the fourth quarter.
Write to Stephen Nakrosis at stephen.nakrosis@wsj.com
(END) Dow Jones Newswires
June 03, 2025 18:10 ET (22:10 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。